Institut Català d'Oncologia

Futó vizsgálatok

• Toboroz

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· 3. fázis· Forrás

• Toboroz

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· 3. fázis· Forrás

• Toboroz

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· 2/3. fázis· Forrás

• Toboroz

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· 3. fázis· Forrás

• Toboroz

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· 3. fázis· Forrás

• Toboroz

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· 3. fázis· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· 3. fázis· Forrás

• Toboroz

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Toboroz

  Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

  NCT07340164· 2. fázis· Forrás

• Toboroz

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· 3. fázis· Forrás

• Toboroz

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· 3. fázis· Forrás

• Toboroz

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· 3. fázis· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· Forrás

• Toboroz

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· 2/3. fázis· Forrás

• Toboroz

  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  NCT07227402· 3. fázis· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· 2. fázis· Forrás

• Toboroz

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· 2. fázis· Forrás

• Toboroz

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· 3. fázis· Forrás

• Még nem toboroz

  Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

  NCT07013851· 2. fázis· Forrás

• Toboroz

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Forrás

• Toboroz

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· 3. fázis· Forrás

• Toboroz

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· 3. fázis· Forrás

• Toboroz

  PALACE: Cemiplimab Trial According to ctDNA Levels

  NCT06917573· 2. fázis· Forrás

• Toboroz

  DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  NCT06953089· 2. fázis· Forrás

• Toboroz

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· 3. fázis· Forrás

• Toboroz

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer

  2024-515884-69-00· 3. fázis· Forrás

• Toboroz

  Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

  NCT07153445· 2. fázis· Forrás

• Toboroz

  Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  NCT06486883· 2. fázis· Forrás

• Toboroz

  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

  NCT06409936· 2. fázis· Forrás

• Toboroz

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· 3. fázis· Forrás

• Toboroz

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· 2/3. fázis· Forrás

• Toboroz

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· 3. fázis· Forrás

• Toboroz

  Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

  NCT06960577· 2. fázis· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· 3. fázis· Forrás

• Toboroz

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· 3. fázis· Forrás

• Toboroz

  LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.

  2022-501315-13-00· 3. fázis· Forrás

• Toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  NCT06767514· 3. fázis· Forrás

• Toboroz

  Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

  NCT06641414· 3. fázis· Forrás

• Fut, nem toboroz

  Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to standard treatment reflecting actual clinical practice in Spain

  2024-513952-13-00· 3. fázis· Forrás

• Fut, nem toboroz

  Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Advanced or Recurrent Endometrial Cancer in Spain.

  2024-514728-17-00· 4. fázis· Forrás

• Fut, nem toboroz

  Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

  NCT06668558· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· 3. fázis· Forrás

• Toboroz

  Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

  NCT06180356· 2. fázis· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Forrás

Showing 50 of 108.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák20 toboroz
• Petefészekrák15 toboroz
• Méhtestrák8 toboroz
• Áttétes emlőrák4 toboroz
• Prosztatarák4 toboroz
• Akut mieloid leukémia (AML)3 toboroz
• Fej-nyaki daganatok3 toboroz
• Hólyagrák3 toboroz
• Méhnyakrák3 toboroz
• Gyermekkori daganatok2 toboroz
• Gyomor- és nyelőcsőrák2 toboroz
• Hasnyálmirigyrák2 toboroz
• Melanóma2 toboroz
• Mielóma multiplex2 toboroz
• Vesedaganat2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Follikuláris limfóma1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Máj- és epeúti rák1 toboroz
• Mezotelióma1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)

  2025-521489-80-00· 2. fázis· Forrás

• Lezárult

  A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.

  NCT06173505· 1/2. fázis· Forrás

• Lezárult

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· 2. fázis· Forrás

• Toboroz

  A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

  NCT06319456· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

  NCT05109975· 1. fázis· Forrás

• Lezárult

  Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trial

  2023-508583-30-00· 1/2. fázis· Forrás

• Lezárult

  Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

  2023-505796-76-00· 1. fázis· Forrás

• Lezárult

  A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  2023-504111-33-00· 2. fázis· Forrás

• Lezárult

  Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

  NCT05092360· 3. fázis· Forrás

• Fut, nem toboroz

  Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

  NCT05222555· 1/2. fázis· Forrás

• Lezárult

  To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

  2024-510644-31-00· 1. fázis· Forrás

• Fut, nem toboroz

  A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

  2024-512127-36-00· 1/2. fázis· Forrás

• Lezárult

  Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negative test.

  2024-511875-14-00· 2. fázis· Forrás

• Lezárult

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT05089734· 3. fázis· Forrás

• Lezárult

  Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

  NCT04811027· 2. fázis· Forrás

• Lezárult

  Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

  NCT04776447· 2. fázis· Forrás

• Lezárult

  A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  NCT04746924· 3. fázis· Forrás

• Fut, nem toboroz

  RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

  NCT04597125· 4. fázis· Forrás

• Lezárult

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· 3. fázis· Forrás

• Leállították

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· 3. fázis· Forrás

• Fut, nem toboroz

  NADIM II: Neo-Adjuvant Immunotherapy

  NCT03838159· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

  NCT03816163· 2. fázis· Forrás

• Fut, nem toboroz

  Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

  NCT05498896· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· 3. fázis· Forrás

• Fut, nem toboroz

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· 3. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· 3. fázis· Forrás

• Lezárult

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· 3. fázis· Forrás